The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

Since allogeneic stem cell transplantation (SCT) represents an intensive curative treatment
for high-risk malignancies, its failure to prevent relapse leaves few options for successful …

Abstract From 2002 to 2007, 103 patients with primary myelofibrosis or postessential
thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis
have occurred over the last decade. Treating physicians now have access to an ever …

The guideline group regarding the diagnosis and management of myelofibrosis was
selected to be representative of UK‐based medical experts, together with a contribution from …

The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

Since the discovery of the JAK 2 V617F mutation in the majority of the myeloproliferative
neoplasms (MPN) of polycythemia vera, essential thrombocythemia and primary …